Low dose oral alpha-interferon therapy for patients seropositive for human immunodeficiency virus type-1 (HIV-1).
Thirty eight symptomatic and two asymptomatic patients seropositive for human immunodeficiency virus type-1 (HIV-1) were treated with a natural human interferon alpha (HuIFN alpha). Patients were given 2 IU/kg HuIFN alpha orally once daily in powdered maltose held in the mouth to promote mucosal absorption. This oral immunomodulating HuIFN alpha therapy resulted in an increase in CD4+ lymphocytes, an increase in weight, and a dramatic alleviation of clinical symptoms related to HIV-1 infection.
Koech
D K
DK
Kenya Medical Research Institute, Nairobi.
Obel
A O
AO
Minowada
J
J
Hutchinson
V A
VA
Cummins
J M
JM
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D015496:CD4-Positive T-Lymphocytes; D005260:Female; D006679:HIV Seropositivity / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage / Q000627:therapeutic use*; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged
D007370:Interferon Type I